
You Are Invited...



to Attend a CME/CE-Accredited Dinner Program



Treatment of CLL and CML in a Rapidly Evolving Therapeutic Landscape

Application to Clinical Practice

Wednesday
January 15, 2020
6:00 pm – 8:30 pm

Hyatt Regency San Francisco

Five Embarcadero Center San Francisco, CA

www.CLRounds.com



Treatment of CLL and CML in a Rapidly Evolving Therapeutic Landscape
Application to Clinical Practice

PROGRAM SUMMARY

The Chronic Leukemia Rounds provides a forum to discuss and share best practices for diagnosis and treatment, including new therapies, clinical trials, side-effect management, treatment adherence, and other issues related to managing patients with a chronic leukemia.

LEARNING OBJECTIVES

At the conclusion of this program, participants will be able to:

- Describe the latest clinical data on prognostic indicators that can be used to inform a specific treatment plan for patients with CLL or CML
- Identify criteria for response assessment and molecular monitoring in the treatment of chronic leukemias
- Consider emerging clinical data on novel agents and emerging therapeutic strategies that have the potential to improve the outcomes for patients with chronic leukemia
- Address potential barriers to treatment adherence for chronic leukemias

REGISTER TODAY! www.CLRounds.com

For additional information, questions, grievances, or assistance with special needs (physical, dietary, etc.) please contact us prior to the program, email info@plexuscomm.com or call 866-607-4333.

PROGRAM CHAIRS

Steven Coutre, MD
Professor of Medicine
(Hematology)
Stanford University
Medical Center
Palo Alto, CA

Neil Shah, MD, PhD

Professor, Department of Medicine (Hematology/Oncology) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Comprehensive Cancer Center UCSF San Francisco, CA

PROGRAM AGENDA

6:00 pm Exhibits/Sign-In/Networking/Dinner

6:30 pm Welcome/Overview

Lauren Berger, MPH - Leukemia & Lymphoma Society

Steven Coutre, MD Neil Shah, MD, PhD

6:50 pm **Defining Treatment Goals and Choice of Optimal Kinase**

Inhibitor Therapy in Chronic Phase CML
Neil Shah, MD, PhD & Kelly Schoenbeck, MD
Helen Diller Comprehensive Cancer Center UCSF

7:25 pm Changing the Treatment Paradigm: Upfront Management

of CLL

Steven Coutre, MD – Stanford University Medical Center

Additional Faculty TBD

7:55 pm Extending Survival: Choices of Therapy for the Relapsed

CLL Patient

Steven Coutre, MD – Stanford University Medical Center

Additional Faculty TBD

8:30 pm Closing Remarks

TARGET AUDIENCE

Healthcare providers that treat patients with chronic leukemia.

Jointly provided by The Leukemia & Lymphoma Society, PleXus Communications, and RUSH University.







CME/CE CONTINUING EDUCATION INFORMATION

In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Physician

Rush University Medical Center designates this Live Activity for a maximum of two (2) AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurse

Rush University is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Rush University designates this live activity for two (2) Continuing Education credits. This activity provides 2.0 ONCC credit hours. This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC certified advanced practice nurses.

Pharmacist

This program is approved for 2.0 hours (0.2 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

There is no fee for participating in this program.



PRESORTED
FIRST-CLASS MAIL
US POSTAGE
PAID
TRENTON NJ
PERMIT 185